GHRP-2

What Is GHRP-2?

GHRP-2, also called pralmorelin, is a synthetic peptide developed to stimulate growth hormone pathways through activation of the ghrelin receptor. As the earliest member of the growth hormone secretagogue class, it has been widely used in experimental endocrinology. The compound has progressed through stage II clinical evaluation for growth impairment and remains under active research for its influence on appetite regulation, muscle preservation, immune activity, and sleep physiology. GHRP-2 demonstrates oral and sublingual effectiveness, distinguishing it from peptides requiring injection.

GHRP-2 Structure

GHRP-2 consists of a short peptide chain engineered for receptor specificity and metabolic stability. Its structural characteristics allow for reliable interaction with growth hormone signaling mechanisms in research applications.

GHRP-2 Effects

1. Skeletal Muscle Protection

Animal studies have shown that GHRP-2 limits muscle loss by decreasing protein degradation while enhancing protein synthesis. Suppression of atrogin-1 and MuRF1 reduces catabolic signaling, while growth hormone and insulin-like growth factor-1 activation promotes anabolic balance in stressed physiological states.

2. Appetite Regulation

GHRP-2 has been observed to increase feeding behavior across multiple experimental models. Appetite stimulation is of interest in research focused on conditions characterized by inadequate nutritional intake and unintended weight loss.

3. Cardiovascular Cellular Effects

Research using cardiac cell cultures and animal models indicates that GHRP-2 reduces apoptosis under stress conditions. Identification of peptide-responsive cardiac receptors has expanded understanding of cardiovascular peptide signaling pathways.

4. Immune Function Enhancement

The peptide has demonstrated the ability to activate thymic tissue, increasing T-cell production and diversity. This effect may be relevant for studying immune system decline associated with aging and chronic disease.

5. Sleep Cycle Influence

GHRP-2 has been shown to alter sleep architecture by extending deep sleep stages and modifying REM sleep distribution. These changes correlate with improved restorative sleep and physiological recovery.

6. Pain Response Modulation

Analgesic effects observed in animal models occurred prior to growth hormone release, indicating direct modulation of pain pathways. GHRP-2 selectively engages opioid receptors involved in pain relief.

Research Use Disclaimer

GHRP-2 has demonstrated acceptable safety margins in animal research, but human safety has not been established. Dosage data from non-human studies are not transferable to humans. The compound is restricted to laboratory and educational research only.

Scientific Attribution

This summary cites peer-reviewed research and acknowledges the scientific work of Dr. Logan, M.D., and Dr. Jean-Alain Fehrentz. References are included solely for academic credit and do not imply endorsement or affiliation.

Referenced Citations

1. R. Hu et al., "Effects of GHRP-2 and Cysteamine Administration on Growth Performance, Somatotropic Axis Hormone and Muscle Protein Deposition in Yaks (Bos grunniens) with Growth Retardation," PloS One, vol. 11, no. 2, p. e0149461, 2016.
2. D. Yamamoto et al., "GHRP-2, a GHS-R agonist, directly acts on myocytes to attenuate the dexamethasone-induced expressions of muscle-specific ubiquitin ligases, Atrogin-1 and MuRF1," Life Sci., vol. 82, no. 9–10, pp. 460–466, Feb. 2008.
3. L. T. Phung et al., "The effects of growth hormone-releasing peptide-2 (GHRP-2) on the release of growth hormone and growth performance in swine," Domest. Anim. Endocrinol., vol. 18, no. 3, pp. 279–291, Apr. 2000.
4. B. Laferrère, C. Abraham, C. D. Russell, and C. Y. Bowers, "Growth hormone releasing peptide-2 (GHRP-2), like ghrelin, increases food intake in healthy men," J. Clin. Endocrinol. Metab., vol. 90, no. 2, pp. 611–614, Feb. 2005.
5. B. Laferrère, A. B. Hart, and C. Y. Bowers, "Obese subjects respond to the stimulatory effect of the ghrelin agonist growth hormone-releasing peptide-2 on food intake," Obes. Silver Spring Md, vol. 14, no. 6, pp. 1056–1063, Jun. 2006.
6. G. Muccioli et al., "Growth hormone-releasing peptides and the cardiovascular system," Ann. Endocrinol., vol. 61, no. 1, pp. 27–31, Feb. 2000.
7. V. Bodart et al., "Identification and characterization of a new growth hormone-releasing peptide receptor in the heart," Circ. Res., vol. 85, no. 9, pp. 796–802, Oct. 1999.
8. D. D. Taub, W. J. Murphy, and D. L. Longo, "Rejuvenation of the aging thymus: growth hormone-mediated and ghrelin-mediated signaling pathways," Curr. Opin. Pharmacol., vol. 10, no. 4, pp. 408–424, Aug. 2010.
9. G. Gopinadh et al., "Prolonged oral treatment with MK-677, a novel growth hormone secretagogue, improves sleep quality in man," Neuroendocrinology, vol. 66, no. 4, pp. 278–286, Oct. 1997.
10. P. Zeng et al., "Ghrelin receptor agonist, GHRP-2, produces antinociceptive effects at the supraspinal level via the opioid receptor in mice," Peptides, vol. 55, pp. 103–109, May 2014.
11. Moulin, A. , Ryan, J. , Martinez, J. and Fehrentz, J. (2007), Recent Developments in Ghrelin Receptor Ligands. ChemMedChem, 2: 1242-1259.